华盛昌(002980) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥194,696,356.01, representing a 1.28% increase year-over-year, but a 30.19% decrease for the year-to-date period at ¥551,730,782.54[4] - Net profit attributable to shareholders for Q3 2021 was ¥44,819,165.75, down 7.16% year-over-year, and down 58.53% year-to-date at ¥130,724,287.03[4] - The basic earnings per share for Q3 2021 was ¥0.34, a decrease of 6.63% year-over-year, and down 63.16% year-to-date[5] - The total operating revenue for the period was CNY 551,730,782.54, a decrease of 30.2% compared to CNY 790,363,549.92 in the previous period[20] - The company reported a decrease in diluted earnings per share to ¥0.34, down 6.63% year-over-year, and down 63.16% year-to-date[5] - The net profit for Q3 2021 was CNY 130,781,983.82, a decrease of 58.6% compared to CNY 315,314,682.29 in the same period last year[22] - The total revenue from operating activities was CNY 638,516,907.33, down 26.7% from CNY 871,712,719.77 in the previous year[25] - The company reported a total comprehensive income of CNY 130,766,302.70, compared to CNY 315,165,522.02 in the prior year[23] - Basic and diluted earnings per share were both CNY 0.98, down from CNY 2.66 in the same quarter last year[23] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was ¥16,136,691.01, reflecting a significant decline of 94.39%[4] - The company's cash and cash equivalents as of September 30, 2021, were CNY 369,727,073.40, compared to CNY 366,837,779.81 at the end of 2020, showing a marginal increase[16] - The cash flow from operating activities showed a net inflow of CNY 16,136,691.01, significantly lower than CNY 287,668,675.20 in Q3 2020[26] - The cash and cash equivalents at the end of the period were CNY 369,727,073.40, a decrease from CNY 627,992,308.60 at the end of Q3 2020[27] - The cash flow from investing activities generated a net inflow of CNY 148,187,398.39, contrasting with a net outflow of CNY 227,850,409.29 in Q3 2020[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,176,518,263.88, a decrease of 1.21% compared to the end of the previous year[5] - The total equity attributable to shareholders was ¥1,043,466,268.04, a decrease of 1.35% from the end of the previous year[5] - The total liabilities were CNY 132,715,851.87, showing a slight decrease from CNY 132,941,532.96 in the previous period[18] - The total assets as of September 30, 2021, were CNY 1,176,518,263.88, a decrease from CNY 1,190,985,051.58 at the end of 2020[19] - The company's net profit for the period was not explicitly stated, but the retained earnings decreased to CNY 286,956,552.45 from CNY 302,899,005.42, a decline of 5.3%[19] Operational Insights - The decline in revenue was primarily attributed to a decrease in sales of pandemic prevention products compared to the previous year, which had seen a significant increase due to COVID-19[9] - Total operating costs amounted to CNY 417,478,695.29, which is a slight decrease of 4.8% from CNY 434,939,278.83 in the previous period[20] - The total operating expenses were CNY 622,380,216.32, an increase from CNY 584,044,044.57 in the same quarter last year[26] - The company reported a decrease in sales revenue from CNY 581,914,813.56 in Q3 2021 compared to CNY 821,342,805.95 in Q3 2020[25] Strategic Developments - The company has obtained EU CE certification and UK MHRA registration for its real-time fluorescence quantitative PCR analyzer product, enhancing its market credibility[14] - The company signed a cooperation agreement with Southern University of Science and Technology to establish a joint laboratory, indicating a strategic focus on R&D collaboration[14] Other Considerations - The company incurred a foreign exchange loss of CNY 15,681.12 in Q3 2021, compared to a loss of CNY 149,160.27 in the previous year[23] - The company has not undergone an audit for the third quarter report, which may affect investor confidence[32] - The company is adapting to new accounting policies, which may impact future financial reporting[32]